Solid Biosciences Inc. Annual Report: A Look Back at This Year

Thinking about Solid Biosciences? Let's explore their performance this past year. We'll see what it might mean for your investment. I'll keep it simple, like we're just chatting.

This report covers their year, which ended on December 31, 2025.

Here's what we'll discuss:

1. What does this company do and how did they perform this year?

   • Solid Biosciences is a biotech company. They are in the clinical stage. They develop gene therapies for rare and serious nerve and heart diseases. Their main programs target Duchenne muscular dystrophy (DMD) and inherited heart conditions. These therapies deliver a working gene. This fixes problems caused by a faulty gene. It addresses the disease's root cause.
   • They use special "delivery vehicles" called AAV capsids. Think of them as tiny trucks. These capsids carry therapeutic genes into the body's cells. One key capsid is POLARIS-101TM. They use it in their Duchenne muscular dystrophy program (SGT-003). They also license it to other companies and researchers. This licensing shows their technology's value. It also brings in money without issuing more shares. They have signed over 50 licensing agreements for POLARIS-101TM. This shows strong outside interest.
   • This year's performance snapshot: They made progress on drug candidates. They advanced many clinical and preclinical programs. However, it was another year of high spending and losses. The company reported a loss of $174.3 million in 2025. This increased from $124.7 million in 2024. They pushed their research and development forward. As of June 30, 2025, the value of their stock available to public investors was about $317.7 million. This shows their market size. They also had about 98.4 million shares of common stock. This was as of March 16, 2026. Regulators classify them as a "Non-accelerated filer" and a "Smaller reporting company." This means their public stock value is under $700 million. Their yearly revenue is under $100 million. They are a smaller public company. They have fewer reporting requirements than larger drug companies.

2. Financial performance - revenue, profit, growth metrics

   • Revenue: Solid Biosciences has not sold any commercial products yet. They do not expect to generate sales revenue soon. This is normal for biotech companies in research. They rely on outside funding, partnerships, or licensing. For the year ended December 31, 2025, the company reported zero revenue.
   • Profit (or Loss): They reported a loss of $174.3 million in 2025. This is a big increase from their $124.7 million loss in 2024. Their loss grew by about 39.8% from last year. This was mainly due to more research and development.
   • Costs to Run the Business (Operating Expenses): Their total operating costs jumped by 38.1%. They went from $129.7 million in 2024 to $179.2 million in 2025. This increase shows more intense work across their drug pipeline.
     • Research and Development (R&D) Expenses: Most of their money goes here. R&D costs rose sharply by 45.5%. They went from $96.4 million in 2024 to $140.3 million in 2025. This big jump is because they are doing more clinical trials. They are also expanding manufacturing. They are developing new early-stage programs.
       • For example, spending on their Duchenne muscular dystrophy program (SGT-003) soared. It rose by 288% to nearly $59 million in 2025. This was mainly due to higher clinical trial costs. They enrolled more patients for INSPIRE DUCHENNE and IMPACT DUCHENNE studies.
       • They also greatly increased spending on a new heart program (SGT-601). It rose over 180% to $7.8 million in 2025. This reflects faster early-stage development.
       • However, spending on another heart program (SGT-501) actually fell. It dropped by 44% to $9.6 million in 2025. This likely happened because they finished some early work. They also moved resources elsewhere.
     • General and Administrative (G&A) Expenses: These are costs not related to R&D. They include executive salaries, legal fees, and accounting. They rose by 16.8%. They went from $33.3 million in 2024 to $38.9 million in 2025. This reflects general company growth and public company costs.
   • Total Losses So Far: As of December 31, 2025, their total losses since starting reached a huge $957.8 million. This big deficit highlights the high cost of drug development. It also shows the company is not yet selling products.

3. Major wins and challenges this year

   • Wins:
     • Regulatory Progress for SGT-501: The FDA gave their SGT-501 program important designations. This program targets CPVT, a rare heart condition. These include Fast Track Designation. This speeds up development and review. They also got Orphan Drug Designation. This offers tax credits and 7 years of market exclusivity. Finally, Rare Pediatric Disease Designation could bring a Priority Review Voucher. This voucher is valuable. They can sell it or use it to speed up another drug's review.
     • Proprietary Technology Validation: Their POLARIS-101TM capsid shows promise. It is a key part of their gene therapies. Clinical trials show it is generally well-tolerated. This was seen in the INSPIRE DUCHENNE study for DMD. Preclinical studies also showed this. They licensed this technology to over 50 other groups. This proves its potential and wide use. It shows its value beyond their own drugs.
     • New Program Advancement: Their early-stage SGT-601 program for TNNT2 dilated cardiomyopathy (DCM) advanced. This is another severe heart condition. Mouse studies showed promising results. It restored heart function and improved survival. This supports its continued development.
     • Significant Funding Secured (After Year-End): In March 2026, after the year ended, Solid Biosciences raised money. They secured about $226.4 million from selling common stock privately. This cash injection greatly strengthens their finances. It extends how long they can operate.
   • Challenges:
     • Growing Losses: Their loss grew significantly by 39.8% from last year. It reached $174.3 million. This reflects the high and rising costs of drug development.
     • No Product Sales: The company is not yet selling products. They are years away from potential sales revenue. This means they rely completely on outside funding. This includes selling stock or partnerships.
     • High Spending: R&D costs soared by 45.5% to $140.3 million in 2025. They spend a lot of cash to keep programs running. This means they need to raise capital often.

4. Financial health - cash, debt, liquidity

   • Cash in the Bank: As of December 31, 2025, Solid Biosciences had $187.9 million. This included cash, cash equivalents, and investments. This was their available cash at year-end.
   • New Funding Boost: They raised $226.4 million in March 2026. This private stock sale greatly improved their cash. It provided a crucial cash injection.
   • How Long Cash Will Last: The company believes their cash, plus the new funding, should last. It should cover their costs into the first half of 2028. However, this estimate depends on many assumptions. These include R&D speed and trial costs. They could use up their cash sooner. This might happen if costs are higher or unexpected.
   • Debt: The report mentions "interest expense" and "derivative liabilities." These relate to milestone payments. Derivative liabilities often come from financial tools. These include warrants or convertible notes. They link to future events or the stock price. These are future obligations or could mean more shares issued.

5. Key risks that could hurt the stock price

   • Need for More Funding: Solid Biosciences will need "substantial additional funding." This is to continue operations past their current cash runway. If they cannot raise this money easily, they might delay or stop drug development. This would severely hurt their future and stock price. Future fundraising could also mean more shares issued, reducing your ownership percentage.
   • Uncertainty of Drug Development: Creating new drugs is very risky and takes a long time. There is no guarantee their trials will succeed. They might not get FDA approval. They might never sell products or make money from sales. Most drug candidates fail in trials. Solid Biosciences might never become profitable.
   • High Operating Costs: They expect high expenses and losses to continue. This is as they advance their drug pipeline. This constant high spending means they need to raise money often. This can be hard in unstable markets.
   • Cash Spending Rate: Their cash runway estimate is based on current plans. Actual expenses could be higher than expected. This could make them run out of money sooner. This would create an urgent need for more funding.
   • Clinical Trial Risks: Their clinical trials (like INSPIRE DUCHENNE, IMPACT DUCHENNE) could fail. They might not meet goals. They could have unexpected safety problems. Patient enrollment might face delays. All these would hurt the stock.
   • Initial Take: The company's annual report has a "Risk Factors" section. This details all potential challenges. It shows what could impact their business and stock price. Investors should review this section carefully. Investing in early-stage biotech companies like Solid Biosciences is very speculative. This is due to drug development risks and no product sales.

6. Competitive positioning

   • Solid Biosciences works in a very competitive field. This is gene therapy for rare diseases. It includes Duchenne muscular dystrophy and heart conditions. Many established drug companies and biotechs are in this space. They develop similar or alternative treatments. Their POLARIS-101TM capsid is unique. They license it to over 50 groups. This suggests valuable technology. It could give them an edge in delivery and safety. Other companies pay to use it. This strongly shows its perceived value. However, competition is fierce. Many companies want market share and clinical success here.

7. Leadership or strategy changes

   • Strategy: Their main strategy is still to advance gene therapy programs. These target rare nerve and heart diseases. A key plan is to invest in new capsid and promoter libraries. This aims to find new AAV capsids. These would have better tissue targeting. They would also cause fewer immune reactions. They would have better gene expression. This could lead to more effective and safer therapies. They expect to choose new capsid candidates from these libraries. This will happen in the second half of 2026. This shows a long-term commitment to innovation. It also strengthens their core technology.

8. Future outlook

   • Continued Research: Solid Biosciences plans to keep spending heavily on clinical trials. This includes INSPIRE DUCHENNE and IMPACT DUCHENNE studies for SGT-003 in DMD. It also covers FALCON and ARTEMIS studies for heart programs. They will also keep advancing early-stage drugs, like SGT-601.
   • New Technology: They look forward to choosing new, better capsid technology. This will come from their libraries in late 2026. This could be the foundation for future gene therapies.
   • Licensing: They aim to license their POLARIS-101TM capsid widely. This is for other companies and universities. This could bring in money without issuing more shares. It would also further prove their platform's value.
   • Financial Outlook: They clearly expect expenses and losses to continue. This is for the foreseeable future. They are still in the clinical development stage. Therefore, they will need to get more funding later. This will sustain operations and advance their drug pipeline.

9. Market trends or regulatory changes affecting them

   • The FDA gave SGT-501 important designations. These include Fast Track, Orphan Drug, and Rare Pediatric Disease. These are very positive regulatory trends. They could greatly speed up its market path. They also offer commercial benefits. Fast Track allows more FDA communication. It can also mean a faster review of the drug application. Orphan Drug gives 7 years of market exclusivity after approval. It also offers tax credits for research. Rare Pediatric Disease makes the company eligible for a Priority Review Voucher. This is a valuable asset upon approval.
   • The wider gene therapy market is growing. This is especially true for AAV capsids. It has rising scientific interest and big investments. More regulatory approvals are happening for various uses. This positive market and regulatory environment helps Solid Biosciences' technology. It also supports their strategy. However, it also brings strong competition.